Exogenous IL‐6 induces mRNA splice variant MBD2_v2 to promote stemness in TP53 wild‐type, African American PCa cells
暂无分享,去创建一个
J. Carpten | B. Bao | W. Sakr | I. Powell | C. Legendre | C. Mitrea | A. Bollig-Fischer | G. Dyson | Emily A. Teslow | Christophe Legendre
[1] S. Gabriel,et al. Exome Sequencing of African-American Prostate Cancer Reveals Loss-of-Function ERF Mutations. , 2017, Cancer discovery.
[2] M. Fischer,et al. Census and evaluation of p53 target genes , 2017, Oncogene.
[3] B. Bao,et al. Treating triple negative breast cancer cells with erlotinib plus a select antioxidant overcomes drug resistance by targeting cancer cell heterogeneity , 2017, Scientific Reports.
[4] E. Schaeffer,et al. Risk of Pathological Upgrading and Up Staging among Men with Low Risk Prostate Cancer Varies by Race: Results from the National Cancer Database , 2017, The Journal of urology.
[5] C. Print,et al. A Study of TP53 RNA Splicing Illustrates Pitfalls of RNA-seq Methodology. , 2016, Cancer research.
[6] Q. Hu,et al. NANOG reprograms prostate cancer cells to castration resistance via dynamically repressing and engaging the AR/FOXA1 signaling axis , 2016, Cell Discovery.
[7] Andrew D. Rouillard,et al. Enrichr: a comprehensive gene set enrichment analysis web server 2016 update , 2016, Nucleic Acids Res..
[8] Xin Chen,et al. Defining a Population of Stem-like Human Prostate Cancer Cells That Can Generate and Propagate Castration-Resistant Prostate Cancer , 2016, Clinical Cancer Research.
[9] J. Mefford,et al. Mutational Landscape of Aggressive Prostate Tumors in African American Men. , 2016, Cancer research.
[10] C. Burns,et al. Targeting JAK kinase in solid tumors: emerging opportunities and challenges , 2016, Oncogene.
[11] E. Hurt,et al. A Novel IL6 Antibody Sensitizes Multiple Tumor Types to Chemotherapy Including Trastuzumab-Resistant Tumors. , 2016, Cancer research.
[12] B. Trock,et al. Characterization of 1577 primary prostate cancers reveals novel biological and clinicopathologic insights into molecular subtypes. , 2015, European urology.
[13] D. Levy,et al. STAT3 regulated ARF expression suppresses prostate cancer metastasis , 2015, Nature Communications.
[14] T. Rebbeck,et al. Novel Biomarker Signature That May Predict Aggressive Disease in African American Men With Prostate Cancer. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] R. Vessella,et al. A Paracrine Role for IL6 in Prostate Cancer Patients: Lack of Production by Primary or Metastatic Tumor Cells , 2015, Cancer Immunology Research.
[16] Ruth Etzioni,et al. Difference in Association of Obesity With Prostate Cancer Risk Between US African American and Non-Hispanic White Men in the Selenium and Vitamin E Cancer Prevention Trial (SELECT). , 2015, JAMA oncology.
[17] P. Brown,et al. Epidemiology, biology, and treatment of triple-negative breast cancer in women of African ancestry. , 2014, The Lancet. Oncology.
[18] J. Korbel,et al. Clinical significance of different types of p53 gene alteration in surgically treated prostate cancer , 2014, International journal of cancer.
[19] M. Rubin,et al. Evidence for Molecular Differences in Prostate Cancer between African American and Caucasian Men , 2014, Clinical Cancer Research.
[20] Jignesh R. Parikh,et al. Alternative splicing of MBD2 supports self-renewal in human pluripotent stem cells. , 2014, Cell stem cell.
[21] Andreas Krämer,et al. Causal analysis approaches in Ingenuity Pathway Analysis , 2013, Bioinform..
[22] K. Kalland,et al. Generation of prostate tumor-initiating cells is associated with elevation of reactive oxygen species and IL-6/STAT3 signaling. , 2013, Cancer research.
[23] M. Cooperberg. Re-examining racial disparities in prostate cancer outcomes. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] N. Maitland,et al. JAK-STAT blockade inhibits tumor initiation and clonogenic recovery of prostate cancer stem-like cells. , 2013, Cancer research.
[25] Ian Chambers,et al. A direct physical interaction between Nanog and Sox2 regulates embryonic stem cell self-renewal , 2013, The EMBO journal.
[26] E. Plimack,et al. AZD1480: a phase I study of a novel JAK2 inhibitor in solid tumors. , 2013, The oncologist.
[27] Aviv Regev,et al. Corrigendum: Comparative analysis of RNA sequencing methods for degraded or low-input samples , 2013, Nature Methods.
[28] I. Powell,et al. Minireview: the molecular and genomic basis for prostate cancer health disparities. , 2013, Molecular endocrinology.
[29] Wei Guo,et al. Wild-type p53 suppresses the epithelial-mesenchymal transition and stemness in PC-3 prostate cancer cells by modulating miR‑145. , 2013, International journal of oncology.
[30] Aliccia Bollig-Fischer,et al. Genes Associated with Prostate Cancer Are Differentially Expressed in African American and European American Men , 2013, Cancer Epidemiology, Biomarkers & Prevention.
[31] K. Hochedlinger,et al. The sox family of transcription factors: versatile regulators of stem and progenitor cell fate. , 2013, Cell stem cell.
[32] R. Sinha,et al. Socioeconomic status, healthcare density, and risk of prostate cancer among African American and Caucasian men in a large prospective study , 2012, Cancer Causes & Control.
[33] David R. Kelley,et al. Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and Cufflinks , 2012, Nature Protocols.
[34] Yongmei Chen,et al. Prostate cancer in men less than the age of 50: a comparison of race and outcomes. , 2011, Urology.
[35] D. Tang,et al. Characterization of sphere-propagating cells with stem-like properties from DU145 prostate cancer cells. , 2011, Biochimica et biophysica acta.
[36] M. Hung,et al. p53 regulates epithelial-mesenchymal transition (EMT) and stem cell properties through modulating miRNAs , 2010, Nature Cell Biology.
[37] J. Pinski,et al. Clinical and Correlative Results of SWOG S0354: A Phase II Trial of CNTO328 (Siltuximab), a Monoclonal Antibody against Interleukin-6, in Chemotherapy-Pretreated Patients with Castration-Resistant Prostate Cancer , 2010, Clinical Cancer Research.
[38] W. Sakr,et al. Evidence supports a faster growth rate and/or earlier transformation to clinically significant prostate cancer in black than in white American men, and influences racial progression and mortality disparity. , 2010, The Journal of urology.
[39] Jing Ma,et al. Gleason score and lethal prostate cancer: does 3 + 4 = 4 + 3? , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[40] Lior Pachter,et al. Sequence Analysis , 2020, Definitions.
[41] N. Maitland,et al. Prostate cancer stem cells: a new target for therapy. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[42] Robyn L Prueitt,et al. Tumor immunobiological differences in prostate cancer between African-American and European-American men. , 2008, Cancer research.
[43] S. Chua,et al. Obesity, metabolic syndrome, and prostate cancer. , 2007, The American journal of clinical nutrition.
[44] Pengbo Liu,et al. Sex-determining region Y box 4 is a transforming oncogene in human prostate cancer cells. , 2006, Cancer research.
[45] Yajun Yi,et al. Molecular Alterations in Primary Prostate Cancer after Androgen Ablation Therapy , 2005, Clinical Cancer Research.
[46] W. Gerald,et al. Gene expression profiling predicts clinical outcome of prostate cancer. , 2004, The Journal of clinical investigation.
[47] J. Cheville,et al. Transcriptional silencing of zinc finger protein 185 identified by expression profiling is associated with prostate cancer progression. , 2003, Cancer research.
[48] Y. Horiguchi,et al. Serum interleukin 6 as a prognostic factor in patients with prostate cancer. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[49] J. Bono,et al. Randomised phase II study of siltuximab (CNTO 328), an anti-IL-6 monoclonal antibody, in combination with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer. , 2012, European journal of cancer.
[50] S. Tonstad,et al. Determinants of inflammatory markers in a bi-ethnic population. , 2011, Ethnicity & disease.
[51] T. Barrette,et al. ONCOMINE: a cancer microarray database and integrated data-mining platform. , 2004, Neoplasia.
[52] A. Gao,et al. Interleukin-6 promotes androgen-independent growth in LNCaP human prostate cancer cells. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[53] R. Oyasu,et al. Interleukin-6 as a paracrine and autocrine growth factor in human prostatic carcinoma cells in vitro. , 1997, Cancer research.
[54] Ministerial Meeting,et al. Summary of the , 1994 .